Short answer
Cardiff Oncology, Inc. (CRDF) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $171,000 (up 42.5% year over year) with net income of −$9M.
Q3 2026 key financials · XBRL
- Revenue
- $171,000
- +42.5% YoY · +64.4% QoQ
- Net income
- −$9M
- +21.3% YoY · +4.1% QoQ
- Operating margin
- -5391.2%
- EPS (diluted)
- −$0.11
- +35.3% YoY · +21.4% QoQ
Source: XBRL data from the Cardiff Oncology, Inc. (CRDF) Q3 2026 10-Q on SEC EDGAR. USD.
Cardiff Oncology, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0.2M vs $0.1M YoY
- R&D expense $5.0M vs $8.2M YoY, SG&A $4.4M vs $3.9M
- Best program: 30 mg onvansertib plus FOLFIRI/bev, ORR 72.2% vs 42.1% SoC
- Cash, equivalents and short-term investments $33.8M at September 30, 2026, operating cash use $33.9M
- Funding projected through Q3 2027, substantial going-concern doubt and additional capital required
Risk Factors
- No material changes from Form 10-K risk factors for year ended December 31, 2025
- Carried-forward risks not specified in provided section
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cardiff Oncology, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.